Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multicentric single arm, open label trial. In this study patients candidated to a
first line of chemotherapy for metastatic colorectal cancer will be treated with 8 cycles of
folfoxiri plus bevacizumab plus nivolumab followed by a maintenance with bevacizumab plus
nivolumab.
Patients who do not progress during chemotherapy phase will receive bevacizumab plus
nivolumab as maintenance therapy.
Patients will be treated until disease progression, unacceptable toxicity or
patient/physician decision.